Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
07:32
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

WFH 2016 World Congress

 

24-28 July 2016 Orlando
FAQs
   
Discussion forum - WFH 2016 World Congress
    Topic - Hemophilia – clinical

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Individual baseline thrombin generation and bleeding rate during personalized prophylaxis with Nuwiq in previously treated patients with severe haemophilia A  Shannely Lowndes 1      7/21/2016 9:10:00 AM  
Safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian2 trial  Harley Souter 1      7/20/2016 3:25:00 PM  
The use of turoctocog alfa for the prevention and treatment of bleeds in patients with hemophilia A: efficacy data from European countries included in the guardian2 clinical trial  Harley Souter 1      7/20/2016 3:24:00 PM  
Striving for a bleed free world an interim analysis from the AHEAD Global & German studies  Alessandro Gringeri 1      7/20/2016 3:17:00 PM  
2nd interim analysis results of the global ahead study in hemophilia A patients  Alessandro Gringeri 1      7/20/2016 3:16:00 PM  
Is there a difference in inhibitor incidence with recombinant products? A meta-analysis of 2000 previously untreated patients  Alessandro Gringeri 1      7/20/2016 3:14:00 PM  
Clinical and biological characteristics of Haemophilic patients in Ouagadougou (Burkina faso)  Brigitte TARDY 1      7/19/2016 2:54:00 PM  
Effect of factor VIII concentration on the risk of spontaneous bleeding following treatment with rFVIII (turoctocog alfa) in patients with severe hemophilia A  Harley Souter 1      7/19/2016 12:48:00 PM  
Local and general tolerability of Advate reconstituted in 2-mL rather than 5-mL SWFI: a pediatric post-authorization safety surveillance study  Jimena Goldstine 1      7/18/2016 6:01:00 PM  
First report of safety and efficacy of a glycoPEGylated FVIII (N8-GP) in previously treated pediatric patients with severe hemophilia Aresults from the international phase 3 pathfinder5 trial  Harley Souter 1      7/15/2016 1:13:00 PM  
Validation of the Colorado Adult Joint Assessment Scale in adult patients with severe hemophilia A  Sharon Funk 1      7/8/2016 5:00:00 PM  
PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A  Elena Santagostino 1      7/8/2016 4:50:00 PM  
Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B  Jian-Ming Gu 1      7/8/2016 4:18:00 PM  
Effect of Moderate Intensity Exercise on Hemostatic Capacity in Adults with Hemophilia A and B: Pilot Study  Michelle Sholzberg 1      7/8/2016 12:19:00 AM  
Impact of training of primary care health professionals and patients with hereditary bleeding disorders on quality of treatment  Alessandra Loureiro 1      7/7/2016 8:42:00 PM  
Long-term Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults/Adolescents With Severe Hemophilia A: United States Subgroup Analysis of A-LONG and ASPIRE  Allison Michaelis 1      7/7/2016 8:26:00 PM  
Post Hoc Analysis to Evaluate the Effect of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Adults and Adolescents with Target Joints and Hemophilia B  Allison Michaelis 1      7/7/2016 8:21:00 PM  
Long-Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Adults/Adolescents With Hemophilia B: Longitudinal Analysis of B-LONG and B-YOND  Allison Michaelis 1      7/7/2016 8:13:00 PM  
The experience of surgery in hemophilia patients with inhibitors  Ilgen Sasmaz 1      7/7/2016 8:07:00 PM  
Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Children With Severe Hemophilia A  Allison Michaelis 1      7/7/2016 8:07:00 PM  
Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults and Adolescents With Severe Hemophilia A  Allison Michaelis 1      7/7/2016 8:00:00 PM  
Long-term safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B  Helen Cathro 1      7/7/2016 7:02:00 PM  
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin (rIX-FP) in hemophilia B patients undergoing surgery  Helen Cathro 1      7/7/2016 6:44:00 PM  
Interim results of a Phase IIIb safety and efficacy extension study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B  Helen Cathro 1      7/7/2016 6:39:00 PM  
Robust Fed-Batch Manufacturing Process of Long Acting Factor VIIa (MOD-5014) in CHO Cells  Laura Moschcovich 1      7/7/2016 7:33:00 AM  
Hematuria is a Frequent Finding on Routine Urinalysis in Pediatric Patients with Hemophilia  Kyle Davis 1      7/7/2016 2:44:00 AM  
Course of target joint bleeding with prophylaxis of a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A  Lisa Patrone 1      7/7/2016 12:58:00 AM  
An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A in 234 Pediatric, Adolescent and Adult Patients  Jennifer Doralt 1      7/6/2016 8:35:00 PM  
Articular condition in children and adolescents with severe hemophilia A on prophylaxis: clinical assessment and ultrasound examination  Ihosvany Fernández Bello 1      7/6/2016 6:25:00 PM  
Carriers of Haemophilia B Leyden: Factor IX levels during life  Karina Meijer 1      7/6/2016 5:03:00 PM  
A case of unexpected moderate haemophilia A in a female neonate within a family with mild haemophilia A in affected males: what happened?  Phillis Lakeman 1      7/6/2016 2:57:00 PM  
Safety and efficacy of a pegylated full-length recombinant factor VIII with extended half-life in previously treated children with hemophilia A  Jennifer Doralt 1      7/6/2016 12:52:00 PM  
Reduction in Dosing Frequency and ABRs in Previously Treated Pediatric (12 years) Patients With Severe Hemophilia A During Prophylactic Treatment With Pegylated Recombinant Factor VIII Compared to Pre-Study Prophylactic Regimen  Jennifer Doralt 1      7/6/2016 12:48:00 PM  
A Study of the seroprevalence of Adenovirus-Associated Virus Vectorserotype AAV5 neutralizing activity and antibodies in Patients with Haemophilia A  Sophia Stanford 1      7/6/2016 10:27:00 AM  
Global hemostatic assay at different target procoagulant acitivity of factor VIII and factor IX  KIYOUNG YOO 1      7/6/2016 10:09:00 AM  
Monitoring for efficacy anc safety during switching to new hemophilic products  Hugh C Kim 1      7/6/2016 5:45:00 AM  
Intracranial haemorrhages (2000-2015): 7 centre pediatric experience in Argentina  Monica Martinez 1      7/6/2016 12:10:00 AM  
Characteristics of pediatric previously treated patients with severe hemophilia A aged less than 12 years experiencing no bleeds during a 6-month prophylactic treatment regimen with pegylated recombinant factor VIII  Jennifer Doralt 1      7/5/2016 1:59:00 PM  
Examination of Reduced Volume APCC (activated prothrombin complex concentrate-(FEIBA) for Accelerated Infusion in Adult Hemophilia A or B Patients with Inhibitors  Jennifer Doralt 1      7/5/2016 1:32:00 PM  
Arteriovenous fistulas for clotting factor administration in adults with severe bleeding disorders  Jerome Teitel 1      7/4/2016 9:55:00 PM  
Immune tolerance induction in adult patients with severe haemophilia A and long lasting inhibitors  Anna Buczma 1      7/3/2016 10:41:00 PM  
Transition to Fc-fusion recombinant factor IX using a pediatric PK based protocol: Real life individualized prophylaxis  Kimberly Jacobson 1      6/30/2016 5:09:00 PM  
Transition to Fc-fusion recombinant factor VIII using a pediatric PK based protocol: Real life individualized prophylaxis  Kimberly Jacobson 1      6/30/2016 4:55:00 PM  
       




Most viewed poster for this congress
Poster: 13
Visits: 590
Title: Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders
Authors: Jay Bryant-Wimp , Jay Bryant-Wimp, RPh
Centre: Integrite Solutions

Poster most viewed in this topic
Poster: 97
Visits: 120
Title: Safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian2 trial
Authors: Elena Santagostino ,
Centre: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital Policlinico, Milan, Italy


 






PosterSessionOnline
Logo Draft
 
Logo Cert